Lucy Scientific Discovery (Lucy Scientific Discovery) EBIT per Share : $-5.53 (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery EBIT per Share?

Lucy Scientific Discovery's EBIT per Share for the three months ended in Dec. 2023 was $-0.67. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.53.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Lucy Scientific Discovery's EBIT per Share or its related term are showing as below:

LSDI's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Lucy Scientific Discovery's EBIT for the three months ended in Dec. 2023 was $-1.18 Mil.

Lucy Scientific Discovery EBIT per Share Historical Data

The historical data trend for Lucy Scientific Discovery's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucy Scientific Discovery EBIT per Share Chart

Lucy Scientific Discovery Annual Data

Trend

Jun21

Jun22

Jun23

EBIT per Share

-1.46

-2.33

-5.53

Lucy Scientific Discovery Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial						-0.12	-2.62	-1.33	-0.91	-0.67

Lucy Scientific Discovery EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Lucy Scientific Discovery's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.022	/	1.270
=	-5.53

Lucy Scientific Discovery's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.175	/	1.765
=	-0.67

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.53

Lucy Scientific Discovery (NAS:LSDI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Lucy Scientific Discovery EBIT per Share Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucy Scientific Discovery (Lucy Scientific Discovery) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (NAS:LSDI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6

Website

https://www.lucyscientific.com

Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.

Executives

Richard D Nanula	director, officer: Executive Chairman	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko	officer: Chief Financial Officer	C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany	director, officer: President and CEO	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy	officer: Chief Scientific Officer	C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6